(Q43234759)

16 November 2017

Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease (English)

1 reference

16 November 2017

Lucio Vilar

1

1 reference

16 November 2017

Luciana A Naves

2

1 reference

16 November 2017

Monalisa F Azevedo

3

1 reference

16 November 2017

Maria Juliana Arruda

4

1 reference

16 November 2017

Carla M Arahata

5

1 reference

16 November 2017

Lidiane Moura E Silva

6

1 reference

16 November 2017

Rodrigo Agra

7

1 reference

16 November 2017

Lisete Pontes

8

1 reference

16 November 2017

Larissa Montenegro

9

1 reference

16 November 2017

José Luciano Albuquerque

10

1 reference

16 November 2017

Viviane Canadas

11

1 reference

16 November 2017

1 June 2010

1 reference

16 November 2017

1 reference

16 November 2017

13

1 reference

16 November 2017

2

1 reference

16 November 2017

123-129

1 reference

https://scigraph.springernature.com/pub.10.1007/s11102-009-0209-8

16 November 2017

0 references

cites work

Pitfalls in the diagnosis of Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS11102-009-0209-8

Pharmacological management of Cushing's syndrome: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-009-0209-8

The role of non-invasive dynamic tests in the diagnosis of Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-009-0209-8

Beneficial effects of high daily dose bromocriptine treatment in Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-009-0209-8

Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-009-0209-8

Macroprolactinoma associated with Cushing's disease, successfully treated with cabergoline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-009-0209-8

New medical treatments in Cushing disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-009-0209-8

21 January 2018

1 reference

12 December 2020

Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas.

1 reference

12 December 2020

The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery

1 reference

12 December 2020

Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment.

1 reference

12 December 2020

Adrenocorticotropin-Secreting Pituitary Adenomas Originate from the Anterior or the Intermediate Lobe in Cushing's Disease: Differences in the Regulation of Hormone Secretion

1 reference

12 December 2020

Cushing's disease: radiation therapy

1 reference

12 December 2020

Dopamine agonists and pituitary tumor shrinkage

1 reference

12 December 2020

Bilateral adrenalectomy for refractory Cushing disease: a safe and definitive therapy

1 reference

12 December 2020

Dopamine receptor expression and function in corticotroph pituitary tumors

1 reference

12 December 2020

Complete remission of Nelson's syndrome after 1-year treatment with cabergoline

1 reference

12 December 2020

New medical approaches in pituitary adenomas

1 reference

12 December 2020

Failure of long-term therapy with sodium valproate in Cushing's disease

1 reference

12 December 2020

ACTH silent adenoma shrinking under cabergoline.

1 reference

12 December 2020

Bromocriptine in Nelson's syndrome and Cushing's disease

1 reference

12 December 2020

Ketoconazole therapy: an efficacious alternative to achieve eucortisolism in patients with Cushing's syndrome

1 reference

12 December 2020

1 reference

12 December 2020

The medical treatment of Cushing's syndrome

1 reference

12 December 2020

Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

1 reference

12 December 2020

The role of dopaminergic depletion in the pathogenesis of Cushing's disease and the possible consequences for medical therapy

1 reference

12 December 2020

The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline

1 reference

12 December 2020

Bromocriptine-responsive Cushing's disease associated with anterior pituitary corticotroph hyperplasia or normal pituitary gland

1 reference

12 December 2020

Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline

1 reference

12 December 2020

Cyproheptadine-Induced Remission of Cushing's Disease

1 reference

12 December 2020

Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement

1 reference

12 December 2020

Medical therapy for Cushing's disease

1 reference

12 December 2020

The Mechanism of the Suppressive Action of Bromocriptine on Adrenocorticotropin Secretion in Patients with Cushing′s Disease and Nelson′s Syndrome*

1 reference

12 December 2020

1 reference

12 December 2020

10.1007/S11102-009-0209-8

Identifiers

DOI

1 reference

Dimensions Publication ID

16 November 2017

0 references

1 reference